Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936390 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,538
- Enrollment target
NCT00936390 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,538 participants.
The verdict
NCT00936390, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,538 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
Interventions
- DRUG bicalutamide
- DRUG flutamide
- RADIATION Dose-Escalated Radiation Therapy
- DRUG LHRH agonist (antagonist) therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,538 participants |
| Start Date | 2009-09 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936390
The ClinicalTrials.gov registry entry for NCT00936390 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,538 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bicalutamide is the first listed.
NCT00936390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00936390 about?
NCT00936390 is a clinical study titled "Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation th...
What is the current status of trial NCT00936390?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,538 participants. The study started on 2009-09. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT00936390?
The interventions under investigation include: bicalutamide (DRUG), flutamide (DRUG), Dose-Escalated Radiation Therapy (RADIATION), LHRH agonist (antagonist) therapy (DRUG).
Who is sponsoring clinical trial NCT00936390?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.